Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-99.94%
0%
-99.94%
6 Months
-99.94%
0%
-99.94%
1 Year
-99.94%
0%
-99.94%
2 Years
-99.98%
0%
-99.98%
3 Years
-99.98%
0%
-99.98%
4 Years
-99.97%
0%
-99.97%
5 Years
-99.99%
0%
-99.99%
BioSenic SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
7.53%
EBIT to Interest (avg)
-9.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.24
Sales to Capital Employed (avg)
0.08
Tax Ratio
0.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.06
EV to EBIT
-4.10
EV to EBITDA
-4.26
EV to Capital Employed
5.44
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-132.63%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.30
-2.50
-192.00%
Interest
1.50
0.70
114.29%
Exceptional Items
-19.10
0.00
Consolidate Net Profit
-29.00
-3.00
-866.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -866.67% vs -200.00% in Dec 2022
About BioSenic SA 
BioSenic SA
Pharmaceuticals & Biotechnology
Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation.The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration.
Company Coordinates 
Company Details
Rue Auguste Piccard 37 , GOSSELIES None : 6041
Registrar Details






